28 Analysis of the Cytomegalovirus (CMV) gB vaccine with MF 59 adjuvant (CMVgB) in CMV seronegative patients with renal failure on a transplant list  by Snydman, D.R. et al.
Infections in Sotid Organ Transptant Recipients Sl 5 
Objectives: To assess the cLinicaL impact of the 4 
human HCoVs in hospitalized patients. 
Methods: ALL patients of our university hospi- 
tals who needed a bronchoatveotar-tavage (BAL) 
for an acute respiratory event were enroLLed. 
BAL specimens were screened by RT-PCR for 
the presence of HCoV-OC43, 229E, NL63 and 
HKU1 and ten other respiratory viruses (influenza 
A-B, respiratory syncytial virus A-B, parainfluenza 
1-2-3, hurnan-rhinovirus, enterovirus and human- 
metapneumovirus ) a  welt as Mycoplasma pneumo- 
niae, Chlamydophila pneumoniae and Legionella 
pneumophila. 
Results: There were 539 cases enroLLed in the 
study and 29 (5.4%) had an HCoV identified in 
the BAL specimen. HCoV-OC43 was the most fre- 
quent (n = 12) foLLowed by HCoV-229E (n = 7), HCoV- 
NL63 (n=6) and HCoV-HKU1 (n=4). The median 
age was 47 years and 69% of the cases were male. 
TranspLantation was the most frequent underlying 
diseases and only 28% patients were not considered 
as immunosuppressed. The microbioLogicaL cultures 
of the BAL were negative for bacteria in 69% cases 
and no other respiratory viruses or herpes were 
identified. Nine patients (31%) were in the intensive 
care unit at the time of the BAL procedure (eight 
of them on mechanical ventilation). Twenty-one 
(72%) patients presented acute respiratory symp- 
toms, sixteen (55%) had cough and sputum, and 
13 (45%) dyspnea. A new chest X-ray infiltrate was 
documented in 18 patients (62%) at the time of the 
BAL procedure. Fifteen (52%) patients were already 
treated for a respiratory infection at the time of 
the BAL. The most frequent final diagnosis was a 
Lower respiratory tract infection that remained of 
unspecified etiology in one third of cases. 
Conclusion: ALL four HCoVs are recovered in bron- 
chotaveotar ravages of hospitalized patients. Our 
analysis uggests that they contributed to respira- 
tory symptoms in most cases. 
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Background: Previous tudies have shown that the 
Live attenuated Towne CMV vaccine improved graft 
survival in CMV seronegative r nal transplant recip- 
ients of CMV seropositive donor organs. However, 
the Towne vaccine is not avaiLabLe and recombinant 
vaccines are being developed. TriaLs have demon- 
strated that recombinant gtycoprotein B CMV vac- 
cine (CMVgB) when combined with the adjuvant 
MF 59 is immunogenic and safe in normal individu- 
aLs. 
Objective: To assess the safety and immunogenic- 
ity of the EMVgB vaccine in immunocompromised 
individuals with renal failure on dialysis, who are 
awaiting renal transplantation. 
Methods: A mutticenter, randomized, placebo- 
controLLed trial in EMV seronegative patients with 
renal failure on transplant Lists. Randomization was 
2:2:1 with doses of EMVgB vaccine at either 20 mcg, 
100 mcg or placebo. Injections were administered 
by intramuscular injection at 0, 1 and 6 months 
post enroLLment. Sera were obtained at enroLL- 
ment, and 1, 1.5, 3, 6, 6.5, 8, and 12 months. 
Patients transplanted post enroLLment were fob 
Lowed but did not continue immunization. Sera 
were tested for antibody to EMVgB by ELISA, and 
for neutralizing antibody to EMV. OnLy a Limited set 
of sera were tested before the trial was halted by 
the sponsor due to stow enroLLment. 
Results: 46 patients were enroLLed: 18 received 
20 mcg per dose, 19 received 100 mcg per dose and 
9 received placebo. Patients were weLL matched for 
degree of renal failure and age. Renal transptanta- 
tion occurred in 14 patients. NeutraLizing antibody 
was transiently present in 1 of 5 patients who 
received 3 doses of the 20 mcg dose. In 5 patients 
who received 3 doses at 100 mcg, neutralizing an- 
tibody was detected in 3 of 5 at titers that ranged 
from 35 to 57. Two patients in the 100mcg dose 
group developed CMV syndromes post transpLanta- 
tion both received only 2 doses of vaccine prior 
to transplantation. A neutralizing antibody titer of 
248 was detected 4 months after infection in one 
subject, the other was not tested. No significant 
adverse events were noted with injections in any 
subject. 
Conclusions: The CMVgB vaccine was safe. Some 
evidence of neutralizing antibody could be de- 
tected in patients at the 100mcg dose. Two pa- 
tients who did not complete the 3 dose series 
developed CMV infection and syndrome. Future 
studies may need to incorporate Larger doses of 
vaccine or an improved adjuvant or both. 
